Specialty Pharmacy

Testing individuals not considered high-risk for hepatitis C virus addresses increase in new infections associated with opioid epidemic.

Celtaxsys’ acebilustat is the first novel anti-inflammatory molecule with the potential to both reduce pulmonary exacerbations and prolong time to first exacerbation.

The rate of disease progression in patients with rheumatoid arthritis (RA) can be associated with a poor prognosis in patients.

Top news of the day from across the health care landscape.

With this approval, nivolumab (Opdivo) offers a new treatment option for patients with small cell lung cancer whose cancer has progressed after 2 or more prior lines of therapy.

Two new studies highlight trends in life expectancy and mortality across high-income countries, citing worsening health in the United States.

Assessment of neurofilament light chain levels offers real-time, efficient measure marker of multiple sclerosis progression.

States that chose to expand Medicaid eligibility under the Affordable Care Act (ACA) have seen a greater decrease in uninsured rates among low-income patients.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

A look at last week's top stories in the world of pharmacy.

The FDA has approved the first generic epinephrine auto-injector for the emergency treatment of allergic reactions, including anaphylaxis.

Lenvatinib (Lenvima) has been granted approval by the FDA as a first-line treatment for patients with unresectable hepatocellular carcinoma.

Surviving cancer during childhood can lead to health problems and depression later in life.

Exposure to secondhand smoke in childhood can lead to greater risk of rheumatoid arthritis later in life, even in non-smoking adults.

A liquid biopsy test examines circulating tumor cells in blood samples of patients with prostate cancer to determine how they will respond to certain therapies.

Top news of the day from across the health care landscape.

Certain magnetic resonance imaging (MRI) parameters correlated with a greater risk of recurrence and progression to multiple sclerosis within the first year following diagnosis of clinically isolated syndrome.

Officials with the FDA have approved ivacaftor (KALYDECO) as the first and only therapy indicated to treat the underlying cause of cystic fibrosis in children aged 12 to

Patients who were more satisfied with the communication they received from cancer care providers often had better health outcomes at lower costs.

Researchers have developed a novel peptide drug that has the potential to reduce tumor growth and slow down the spread of cancer cells.

Top news of the day from across the health care landscape.

Treating patients’ stress and poor sleep may help reduce the risk of depression in multiple sclerosis.

A phase 1 trial evaluating the safety and tolerability of PRN2246, a Bruton's tyrosine kinase (BTK) inhibitor, found the drug having no serious medication-related adverse events in healthy volunteers while also being able to reach the brain.

The 2018-19 Best Hospital’s Honor Roll is a distinction awarded to 20 hospitals delivering exceptional treatment across multiple areas of care.

Globally, lung cancer mortality rates among women are projected to increase by 43% from 2015 to 2030.

Botox injections found to decrease urinary incontinence and improve quality of life for patients with multiple sclerosis.

Organ transplant recipients who received infected kidneys were cured of hepatitis C after taking antiviral therapy following the procedure.

Top news of the day from across the health care landscape.

Migalastat (Galafold, Amicus Therapeutics) is the first oral medication for the treatment of adults with Fabry disease, a rare genetic disorder.